TW202110434A - 用於轉移性或晚期乳癌患者的6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸 - Google Patents

用於轉移性或晚期乳癌患者的6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸 Download PDF

Info

Publication number
TW202110434A
TW202110434A TW109115366A TW109115366A TW202110434A TW 202110434 A TW202110434 A TW 202110434A TW 109115366 A TW109115366 A TW 109115366A TW 109115366 A TW109115366 A TW 109115366A TW 202110434 A TW202110434 A TW 202110434A
Authority
TW
Taiwan
Prior art keywords
patients
treatment
patient
dose
compound
Prior art date
Application number
TW109115366A
Other languages
English (en)
Chinese (zh)
Inventor
卡通 希爾維因 卡特
馬瑞納 賽拉諾維克
派翠克 柯恩
高蒂耶 波歐
Original Assignee
法商賽諾菲公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商賽諾菲公司 filed Critical 法商賽諾菲公司
Publication of TW202110434A publication Critical patent/TW202110434A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109115366A 2019-05-09 2020-05-08 用於轉移性或晚期乳癌患者的6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸 TW202110434A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP19305593 2019-05-09
EP19305593.6 2019-05-09
EP19305679.3 2019-05-28
EP19305679 2019-05-28
US201962945311P 2019-12-09 2019-12-09
US62/945,311 2019-12-09

Publications (1)

Publication Number Publication Date
TW202110434A true TW202110434A (zh) 2021-03-16

Family

ID=70681807

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109115366A TW202110434A (zh) 2019-05-09 2020-05-08 用於轉移性或晚期乳癌患者的6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸

Country Status (13)

Country Link
US (2) US20200352905A1 (https=)
EP (1) EP3965758A1 (https=)
JP (1) JP2022531898A (https=)
KR (1) KR20220006553A (https=)
CN (1) CN114173776A (https=)
AU (1) AU2020268762A1 (https=)
BR (1) BR112021022216A2 (https=)
CA (1) CA3146346A1 (https=)
IL (1) IL287805A (https=)
MX (1) MX2021013711A (https=)
SG (1) SG11202111979SA (https=)
TW (1) TW202110434A (https=)
WO (1) WO2020225375A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7413363B2 (ja) 2018-09-07 2024-01-15 サノフイ メチル６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボキシレートの調製方法
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
KR20220113695A (ko) 2019-12-09 2022-08-16 사노피 7h-벤조[7]아눌렌-2-카르복실산 유도체의 결정질 형태
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
EP4247363A1 (en) * 2020-11-23 2023-09-27 Sanofi Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
TWI837605B (zh) * 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
CN117042771A (zh) * 2021-03-09 2023-11-10 伊莱利利公司 使用serd给药方案的组合治疗癌症的方法
TW202400136A (zh) * 2022-03-13 2024-01-01 法商賽諾菲公司 以安森司群(amcenestrant)治療乳癌
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19833786A1 (de) * 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
WO2015082990A1 (en) * 2013-12-06 2015-06-11 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
JP7019422B2 (ja) * 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
SMT202300018T1 (it) * 2015-12-09 2023-03-17 Univ Illinois Downregolatori del recettore degli estrogeni a base di benzotiofene
LT3416962T (lt) * 2016-02-15 2021-07-12 Sanofi 6,7-dihidro-5h-benzo[7]anuleno dariniai kaip estrogenų recepptoriaus moduliatoriai
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid

Also Published As

Publication number Publication date
KR20220006553A (ko) 2022-01-17
IL287805A (en) 2022-01-01
US20200352905A1 (en) 2020-11-12
EP3965758A1 (en) 2022-03-16
JP2022531898A (ja) 2022-07-12
AU2020268762A1 (en) 2021-12-02
WO2020225375A1 (en) 2020-11-12
MX2021013711A (es) 2021-12-10
CA3146346A1 (en) 2020-11-12
US20240091194A1 (en) 2024-03-21
SG11202111979SA (en) 2021-11-29
BR112021022216A2 (pt) 2021-12-28
CN114173776A (zh) 2022-03-11

Similar Documents

Publication Publication Date Title
TW202110434A (zh) 用於轉移性或晚期乳癌患者的6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸
CN109310754A (zh) 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法
US20250127759A1 (en) Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
TW202602448A (zh) 用於乳癌治療之組合療法
CN120302972A (zh) 用于治疗转移性去势抵抗性前列腺癌的他拉唑帕利和恩扎卢胺的组合
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
US20240173293A1 (en) Treatment of Breast Cancer with Amcenestrant and Palbociclib
WO2023049363A1 (en) Sotorasib and afatinib for treating cancer comprising a kras g12c mutation
TW202300153A (zh) 使用serd組合給藥方案治療癌症之方法
CN112535688A (zh) 药物组合
Kim et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer
KR20240083178A (ko) Kras g12c 돌연변이를 포함하는 암의 치료를 위한 소토라십 및 egfr 항체
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
WO2022261025A1 (en) Methods of treating cancer with a combination of sotorasib and trametinib
RU2854294C2 (ru) Ингибитор cdk4 для лечения рака
US20250268900A1 (en) Combination therapy using a substituted pyrimidin-4(3h)-one and nivolumab as well as its use in the treatment of cancer
WO2025101623A1 (en) Methods of treating cancer
KR20250170664A (ko) 암 치료에서 소토라십/카보플라틴/페메트렉시드에 대한 투여량 양생법
CN117580572A (zh) 用安森司坦和帕博西尼治疗乳腺癌
HK40126893A (zh) 索托拉西布/卡铂/培美曲塞在癌症治疗中的剂量方案
JP2026513999A (ja) 癌治療におけるソトラシブ／カルボプラチン／ペメトレキセドについての投与計画
CN121219284A (zh) 治疗具有促细胞分裂原活化蛋白激酶(mapk)通路改变的实体瘤的方法
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
JP2025505381A (ja) フタラジノン誘導体を含む抗癌剤との併用投与用薬学的組成物